Toluene-4-sulphonohydrazide

Endpoint summary

Description of key information

Acute toxicity, oral: 

A LD50 value in rats of 283 mg/kg for p-TSH (T) is indicated in the ChemIDplus database, however, no specific reference is indicated and thus the validity of this information cannot be assessed.

 

No data is available for Toluene-4-sulphonohydrazide (TSH). However, QSAR prediction data (accessed on the 14-02-2022) shows that oral LD50 in rats and mice is 320 mg/kg bw/day and 1300 mg/kg bw/day, respectively. The predictions had a moderate prediction quality i.e., 0.59 and 0.52 for rats and mice, respectively. Furthermore, in an OECD guideline 489 (in vivo mammalian alkaline comet assay), Wister rats were treated by oral gavage with Toluene-4-sulphonohydrazide, mortality was observed at a dose of 250 mg/kg bw/day in males.

Based on this TSH should be classified as Acute tox 3 H301.

 

Acute toxicity, dermal: 

No data available for p-TSH.

No data and low concern of acute toxicity via dermal exposure.

 

Acute toxicity, inhalation:

No reliable experimental data is available for TSH.

The presumed breakdown product of Toluene-4-sulphonohydrazid, hydrazine (CAS No. 302-01-2) shows an LC50 of 570ppm (0.759 mg/L); and has a harmonized classification for Acute Tox. 3, H331 (toxic if inhaled).

Based on this TSH should be classified as Acute Tox. 3, H331.

 

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Value:

> 250 - < 320 mg/kg bw

Quality of whole database:

Based on prediction data from the Danish (Q)SAR database (accessed on 14-02-2022) as well as an OECD guideline 489 study.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LC50

Value:

570

Quality of whole database:

Based on acute toxicity data for hydrazine, a presumed breakdown product of the target substance.

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Quality of whole database:

No concerns for acute toxicity via dermal exposure

Additional information

Justification for selection of acute toxicity – oral endpoint
QSAR prediction data shows that oral LD50 in rats and mice is 320 mg/kg bw/day and 1300 mg/kg bw/day, respectively. The predictions had a moderate prediction quality i.e., 0.59 and 0.52 for rats and mice, respectively. Furthermore, in an OECD guideline 489 (in vivo mammalian alkaline comet assay) where Wister rats were treated by oral gavage with the Toluene-4-sulphonohydrazide, mortality was observed at a dose of 250 mg/kg bw/day in males. Based on overall data for TSH, it is considered appropriate to classify toluene-4-sulphonohydrazide (TSH) as Acute Tox. 3, H301 without further testing.

Justification for selection of acute toxicity – inhalation endpoint

data on the presumed breakdown product of Toluene-4-sulphonohydrazid, hydrazine (CAS No. 302-01-2) shows an LC50 of 570ppm (0.759 mg/L); and has a harmonized classification for Acute Tox. 3, H331 (toxic if inhaled). Based on the acute toxicity of the presumed breakdown product, hydrazine, it is considered appropriate to classify toluene-4-sulphonohydrazide as Acute Tox. 3, H331 without further testing.

Justification for selection of acute toxicity – dermal endpoint
No reliable dermal acute toxicity study is available and overall there is low concerns for acute toxicity via dermal exposure.

Justification for classification or non-classification

According to CLP criteria Toluene-4-sulphonohydrazide (TSH) should due to the identified oral LD50 value and the LC50 value be classified as Acute tox 3; H302 (oral) and Acute tox 3; H331 (inhalation).